These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 21811783)

  • 1. Lymphopenia following the completion of first-line therapy predicts early relapse in patients with diffuse large B cell lymphoma.
    Aoki T; Nishiyama T; Imahashi N; Kitamura K
    Ann Hematol; 2012 Mar; 91(3):375-82. PubMed ID: 21811783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
    Tai WM; Chung J; Tang PL; Koo YX; Hou X; Tay KW; Quek R; Tao M; Lim ST
    Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients with diffuse large B cell lymphoma in partial response or stable disease after first-line R-CHOP: the prognostic value of the absolute lymphocyte count and impact of autologous stem cell transplantation.
    Hung MH; Yu YB; Huang YC; Liu HT; Hong YC; Hsiao LT; Liu JH; Gau JP; Chiou TJ; Chen PM; Tzeng CH; Liu CY
    Ann Hematol; 2012 Dec; 91(12):1907-15. PubMed ID: 22885989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma.
    Porrata LF; Rsitow K; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Habermann TM; Witzig TE; Colgan JP; Nowakowski GS; Thompson CA; Markovic SN
    Leukemia; 2010 Jul; 24(7):1343-9. PubMed ID: 20485372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.
    Oki Y; Yamamoto K; Kato H; Kuwatsuka Y; Taji H; Kagami Y; Morishima Y
    Eur J Haematol; 2008 Dec; 81(6):448-53. PubMed ID: 18691256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan.
    Tanaka T; Shimada K; Yamamoto K; Hirooka Y; Niwa Y; Sugiura I; Kitamura K; Kosugi H; Kinoshita T; Goto H; Nakamura S
    Ann Hematol; 2012 Mar; 91(3):383-90. PubMed ID: 21822617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study on nm23-H1 expression in diffuse large B-cell lymphoma that was treated with CyclOBEAP plus rituximab therapy.
    Niitsu N; Tamaru J; Yoshino T; Nakamura N; Nakamura S; Ohshima K; Nakamine H; Okamoto M
    Ann Hematol; 2011 Feb; 90(2):185-92. PubMed ID: 20809421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
    Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
    Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma.
    Porrata LF; Ristow K; Habermann TM; Witzig TE; Inwards DJ; Markovic SN
    Am J Hematol; 2009 Feb; 84(2):93-7. PubMed ID: 19123458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The lower peripheral blood lymphocyte/monocyte ratio assessed during routine follow-up after standard first-line chemotherapy is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma.
    Yan-Li L; Kang-Sheng G; Yue-Yin P; Yang J; Zhi-Min Z
    Leuk Res; 2014 Mar; 38(3):323-8. PubMed ID: 24439567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era.
    Watanabe R; Tomita N; Itabashi M; Ishibashi D; Yamamoto E; Koyama S; Miyashita K; Takahashi H; Nakajima Y; Hattori Y; Motohashi K; Takasaki H; Ohshima R; Hashimoto C; Yamazaki E; Fujimaki K; Sakai R; Fujisawa S; Motomura S; Ishigatsubo Y
    Eur J Haematol; 2014 Mar; 92(3):204-10. PubMed ID: 24283206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of Prognosis for Patients with Diffuse Large B-Cell Lymphoma Refractory to or in First Relapse After Initial R-CHOP Therapy: A Single-Institution Study.
    Yamamoto M; Watanabe K; Fukuda T; Miura O
    Anticancer Res; 2017 May; 37(5):2655-2662. PubMed ID: 28476841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP.
    Samaras P; Heider H; Haile SR; Petrausch U; Schaefer NG; Siciliano RD; Meisel A; Mischo A; Zweifel M; Knuth A; Stenner-Liewen F; Renner C
    Ann Hematol; 2010 Aug; 89(8):783-7. PubMed ID: 20204361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EBV-positive diffuse large B-cell lymphoma of the elderly: a case series from Peru.
    Beltran BE; Castillo JJ; Morales D; de Mendoza FH; Quinones P; Miranda RN; Gallo A; Lopez-Ilasaca M; Butera JN; Sotomayor EM
    Am J Hematol; 2011 Aug; 86(8):663-7. PubMed ID: 21761432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment serum level of 15-kDa granulysin might have a prognostic value in patients with diffuse large B cell lymphoma.
    Park Y; Choi YJ; Park SJ; Lee SR; Sung HJ; Park KH; Kim SJ; Choi CW; Jung KY; Kim BS
    Acta Haematol; 2011; 126(2):79-86. PubMed ID: 21540579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab.
    Meyer PN; Fu K; Greiner T; Smith L; Delabie J; Gascoyne R; Ott G; Rosenwald A; Braziel R; Campo E; Vose J; Lenz G; Staudt L; Chan W; Weisenburger DD
    Am J Clin Pathol; 2011 Jan; 135(1):54-61. PubMed ID: 21173124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma.
    Huang YC; Liu CJ; Liu CY; Pai JT; Hong YC; Teng HW; Hsiao LT; Chao TC; Gau JP; Liu JH; Hsu HC; Chiou TJ; Chen PM; Yu YB; Tzeng CH
    Ann Hematol; 2011 Oct; 90(10):1145-51. PubMed ID: 21647583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era.
    Takahashi H; Tomita N; Yokoyama M; Tsunoda S; Yano T; Murayama K; Hashimoto C; Tamura K; Sato K; Ishigatsubo Y
    Cancer; 2012 Sep; 118(17):4166-72. PubMed ID: 22213346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.
    Park YH; Lee JJ; Ryu MH; Kim SY; Kim DH; Do YR; Lee KH; Oh SJ; Kim YK; Suh CW; Heo DS; Ryoo BY; Kim JK; Song HS; Lee WS; Kim HJ; Bang YJ; Yang SH; Sohn SK; Kang YK;
    Ann Hematol; 2006 Apr; 85(4):257-62. PubMed ID: 16416337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral blood lymphocyte/monocyte ratio predicts outcome for patients with diffuse large B cell lymphoma after standard first-line regimens.
    Li YL; Pan YY; Jiao Y; Ning J; Fan YG; Zhai ZM
    Ann Hematol; 2014 Apr; 93(4):617-26. PubMed ID: 24141331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.